KR20050005630A - Lonicera japonica extract having activity of enhancing IGF-1 secretion, its process method, and application - Google Patents

Abstract

PURPOSE: Provided are the Lonicera japonica extract having activity of enhancing IGF-1 secretion, a method for manufacturing the same by extracting Lonicera japonica with water, alcohol or their mixture, and the application thereof. Therefore, the extract is orally or non-orally administered to children and adults having decreased IGF-1(Insulin-like Growth Factor-1) secretion activity. CONSTITUTION: The composition for inducing and/or enhancing IGF-1(Insulin-like Growth Factor-1) secretion is characterized by containing, as an active ingredient, 0.0001-10 wt.% of the extract of Lonicera japonica. The extract contains at least one active ingredient selected from the group consisting of loniceroside A, B, C, hederagenin derivative, lonicerin, loganin and iridoid glycosides including vogeloside and Epi-vogeloside.

Description

Lonera japonica extract having activity of enhancing IGF-1 secretion, its process method, and application}

The present invention relates to a method for producing IGF-1 secretion induction (Lonicera japonica) extract, an extract obtained by the above method and various types of compositions comprising the same as an active ingredient, more specifically, the indongcho is water, Preparation method of Indongcho extract extracted by adding alcohol or mixed solvent of alcohol and water, Indongcho extract to induce IGF-1 secretion prepared by the above method and pharmaceutical composition, cosmetic composition and health food composition comprising the same as an active ingredient Etc.

Insulin-like Growth Factor-1 (IGF-1) is a single-chain polypeptide consisting of 70 amino acids and is primarily secreted by the liver. IGF-1 exerts its function through the IGF-1 receptor. Many studies have been conducted on the in vivo function of IGF-1, and such studies have identified various functions other than promoting growth of IGF-1 (eg, promoting protein synthesis, reducing blood glucose levels, and promoting cell differentiation). For example, Arsenijevic Y. et al, J. Neurosci., 15; 21 (18): 7194 (2001) report that IGF-1 is essential for the proliferation of neuronal stem cells, and Cappola AR. et al., J. Clin. Endocrinol. Metab., 86 (9): 4139 (2001) report a direct correlation between decreased muscle strength and decreased motor performance and decreased in vivo concentrations of IGF-1 in older women. In addition, reports that skeletal muscle regeneration can be accomplished via IGF-1 have been reported by Shiotani A. et al., Gene Ther. 8 (14): 1043 (2001), and it has been reported that the bioavailability of IGF-1 is greatly reduced after ethanol overdose (Rojdmark S. et al., J. Endocrinol. Invest., 24 (7): 476 (2001). On the other hand, it has been reported that IGF-1 plays an important role in cell proliferation (Singleton JR. Et al., Neurobiol. Dis. 8 (4): 541 (2001)), and diabetic patients (types 1 and 2). It has also been reported that IGF-1 has therapeutic effects in the form (Thraikill KM, Diabetes Technol Ther., 2 (1): 69-80 (2000)). Seck T. et al. Found that low blood levels of IGF-1 were directly associated with femoral decline in postmenopausal women (Clin. Endocrinol., 55 (1): 101 (2001)). , Conti E. et al., Reported a rapid decrease in IGF-1 in the acute phase of myocardial infarction (J. Am. Coll. Cardiol., 38 (1): 26 (2001)).

Various reports have shown that IGF-1 has cellular protection against ischemia-reperfusion injury in various organs. Nakao Y. et al., J. Thorac Cardiovasc. Surg., 122 (1): 136 (2001) report that IGF-1 has the ability to inhibit neuronal cell death. In addition, IGF-1 deficiency leads to a lack of postnatal growth, delayed mental development, microcephaly and insensitivity of sensory nerves, and in patients with these symptoms, growth hormone is normally secreted and signaling by growth hormone is normally achieved. However, it has been reported that IGF-1 is not produced locally or systemically (Woods KA. Et al., N. Engl. J. Med., 335: 1363 (1996)). On the other hand, administration of IGF-1 to patients deficient in IGF-1 has been reported to improve gymnastics, insulin sensitivity, bone mineral density and length growth (KA Woods. Et al., J. Clin. Endocri. Met., 85: 1407 (2000). There is also a report used to treat polycystic kidney disease (US Pat. No. 5,985,830). In addition, Blum et al. (J. Clin. Endocrinol. Metab. 76: 1610-1616 (1993)) reports that children with low levels of IGF-1 and IGF binding protein 3 (IGFBP-3) in the blood are short and tall Older children reported high levels of IGF-1. In another paper, long-term treatment of IGF-1 has been reported to be effective in increasing key growth rates (Ranke et al., Horm. Res. 44: 253-264 (1995)). It was found to be effective in the treatment of patients lacking growth hormone.

As described above, IGF-1 functions in vivo in a variety of functions, acts cooperatively or separately with the growth hormone, and in vivo by the growth hormone signal or individually. It can be seen that it has various functions.

The present inventors have shown that the extract of Indongcho (or may also be referred to as Phosphorus, which is the same meaning), which has been conventionally used as a herbal medicine, exhibits the effect of inducing the secretion of IGF-1, which exerts the various functions described above, as well as its safety. Thus, the present invention has been completed by confirming that various types of compositions including extracts from Indongcho are innocuous to humans or animals.

Accordingly, it is an object of the present invention to provide a variety of compositions, such as pharmaceutical composition, cosmetic composition, food for inducing IGF-1 secretion. Another object of the present invention is to provide a health food for enhancing physiological activity having the purpose of treating and preventing various growth and physiological diseases caused by aging. Another object of the present invention to provide a method for producing a component having IGF-1 secretion induction activity from Indongcho.

1 is a graph showing the concentration change of blood IGF-1 by the extract of Indongcho of the present invention

According to one aspect of the present invention, the present invention provides a pharmaceutical composition comprising: (a) a pharmaceutically effective amount of an extract of Indongcho extract extracted by hydrothermal treatment and then adsorbed onto the HP-20, which is an adsorbent resin; And (b) provides a pharmaceutical composition for inducing IGF-1 (Insulin like Growth Factor-1) secretion comprising a pharmaceutically acceptable carrier.

The pharmaceutical composition of the present invention which induces the above-described IGF-1 secretion may be administered to a subject having reduced in vivo production of IGF-1 to improve various symptoms and diseases. For example, it can improve gymnastics, insulin sensitivity, bone mineral density and length growth, and also inhibit mental retardation, microcephaly, insensitivity of sensory nerves and femoral decline in postmenopausal women, and inhibit the proliferation of nerve cells. Decrease in muscle strength in older women with osteoarthritis, including osteoarthritis, by promoting chronic stress, insomnia, metabolic disorders, decreased sexual capacity, cartilage regeneration and proliferation, and synthesis of glycosaminoglycans And a decrease in motor performance. And it can promote growth for children and adolescents whose growth plates are not closed but who are slow or lacking.

The candidate substance that can be used as a secretion inducing agent of IGF-1 having such various functions was used as a herbal medicine in the present invention, because the herbal medicine is a natural substance and has been used as a medicine in the past and its stability has been proved. Among them, Indongcho showed the best induction effect of IGF-1.

Indong is a semi-evergreen vine shrub of the Capriofoliaceae family that grows under the forests of the country's wild field, and the bud is called 'Gold Silver Coin' and the leaves and stems are called 'Indongdeung'. This is a plant that has been widely used in herbal medicine. The active ingredients contained in phosphorus and the like so far are known as lonerin (luteolin-7-rhamnoglucoside), caffeoylquinicacid, methyl caffeate, chlorogenic acid, iso-chlorogenic acid (iso flavonoids such as -chlorogenic acid; Biflavonides, such as ochnaflavon; A kind of saponin is fulvotomentoside A, α-hederin, sapindoside B, and new material Loniceroside A identified by the present inventors, B (Korean Patent Publication No. 94-2267); Contains iridoid glycosides such as Loganin, Vogeloside, Epi-vogeloside, etc. Turned out to be. These sinus has been widely used in arthritis, bronchitis, asthma, etc., since the prosthesis is effective for all scabs (inflammation of the inside and the outside), and in recent years, pandemic flu, various purulent infections, moist fever It is known to be effective in restoring joint redness, swelling, hepatotoxicity, and recovery of decreased cellular immunity.

However, there have been no published studies on the effects of promoting IGF-1 secretion in the traditional Chinese medicine or related literature, as most of them mention only herbal medicines for the human body. Patent 0163813 is effective in maximizing the extraction efficiency of herbal ingredients of phosphorus and using the phosphorus more scientifically to extract stems and leaves of phosphorus during the growth period with the highest content of active substance and optimizing the addition ratio of stems and leaves. The method of extracting the active ingredient was determined, and at the same time, the method of extracting the active ingredient having anti-inflammatory analgesic physiological activity with the most active composition by controlling the timing of extracting the phosphorus and the mixing ratio of the leaves and stems, There is a patent on the herbal composition, and Kang et al. (Application No. 1992-0011752) patent for the isolation and effectiveness of bifurabonoids effective against anti-inflammatory, anti-allergic and anti-rheumatic, Kang et al. A patent has been filed for the isolation and structure determination of a headraginin glycoside single material.

Hereinafter, the present invention will be described in detail.

The present invention relates to IGF-1 secretion promoting effect by extracting and purifying the active ingredient from the phosphorus. The phosphorus usable in the present invention can be used to extract flowers, leaves, fruits, stems, roots, etc. of the phosphorus regardless of the harvested season. It can be used as a material for hormone secretagogues. In addition, the present invention provides a herbal composition containing Loniceroside A, Lonieroside B, C, hedragenin derivative, Lonicerin, Loganin extracted from phosphorus Include.

Referring to the present invention in more detail as follows.

The present invention is a method for extracting and purifying an active ingredient having excellent IGF-1 secretion-promoting physiological activity from the stems and leaves of the phosphorus. Can be maximized.

In the present invention, the mixed herbal leaves and stems of the herbal medicines extracted with water, 8 to 12 times the weight of the herbal raw material is added by reflux extraction for about 5 hours and then filtered to collect the filtrate, and the residue 3 again the weight of the herbal raw material weight The water extraction efficiency is increased by adding ˜7 times of water, heating and filtration to mix the filtrate with the previous filtrate. The herbal residue was removed from the water extract by centrifugation and filtration, and then the separation solution was adsorbed onto HP-20 as an adsorbent to separate the bioactive component fraction. The column to which the physiologically active component was adsorbed was sufficiently washed with water and then eluted with ethanol. The eluted solution was concentrated under reduced pressure at 50 degrees and dried in vacuo.

As a result of analyzing the IGF-1 secretion-promoting effective biologically active substance of the standardized fraction extracted from the leaves and stems of the phosphorus by the method according to the present invention as described above, as well as Loneroside A, B Loganin, Lonicerin, etc. are included. Therefore, when the herbal composition is prepared and used as a powder extract obtained by the extraction and purification method according to the present invention, it can be usefully used as an IGF-1 secretagogue.

The herbal composition prepared from the powder extract according to the present invention may be formulated in a conventional manner, and then administered in the form of tablets, soft capsules, injections, etc., and the bases, for example, lactose (Lactose), fine Base components such as crystalline cellulose and magnesium stearate may be mixed with a phosphorus powder extract in a predetermined ratio, and preferably in a ratio of 1: 1.5 to 1.5: 1, compared to the conventional one. It exhibits superior IGF-1 secretagogue activity. In particular, when the herbal composition of the present invention is administered to the human body, there is little concern about side effects compared to other synthetic drugs because it is a natural extract, and as an example of such side effects reduction, a non-steroidal anti-inflammatory drug (NSAID) -based drug is represented. It has been demonstrated in animal model experiments for gastrointestinal disorders and ulcerative side effects.

That is, the phosphorus extract prepared in the present invention was excellent in promoting IGF-1 secretion (see Experimental Example), and the general phosphorus extract was found to be completely nontoxic as a result of an acute toxicity test for mice and rats. It became. (LD ₅₀ = 5 g ext's / Kg or more, Journal of Pharmacognosy Vol. 25, No. 4, 1994).

As described above, according to the present invention, by extracting and purifying the active physiologically active ingredient from the phosphorus, the phosphorus extract, which was conventionally used only in the form of a herbal medicine, can be administered in a convenient powder, ointment, tablet, or injection formulation. It has an effect.

Accordingly, the present inventors have completed the present invention by studying the physiological activity of the extract of Indongcho, revealing that the extract of Indongcho acts as an IGF-1 secretagogue to increase the production of IGF-1

The above-described preparation method for preparing the composition of the present invention has the advantage that can be easily carried out, while separating the key components having a high purity, high yield and economically IGF-1 secretion action. The pharmaceutical composition of the present invention has pharmacological effects such as treatment for length growth retardation, promotion of length growth, improvement of bone mineral density (prevention and treatment of osteoporosis), inhibition of aging, improvement of gymnastics, treatment of femoral decline in postmenopausal women, kidney disease Improvement, ischemic heart disease, chronic stress-related disorders, insomnia, metabolic disorders, decreased sexual capacity, decreased muscle strength and decreased motor performance in older women, cartilage regeneration and proliferation, and synthesis of glycosaminoglycans. To promote degenerative arthritis including osteoarthritis and the protection of neurons.

Suitable dosages of the pharmaceutical compositions of the present invention may vary depending on factors such as the formulation method, mode of administration, age, weight, sex, morbidity, condition of food, time of administration, route of administration, rate of excretion and response to response of the patient. Can be. The pharmaceutical composition for promoting IGF-1 secretion of the present invention contains the extract of Indongcho as an active ingredient. The Inchocho extract can be administered orally or parenterally during clinical administration and can be used in the form of a general pharmaceutical formulation. That is, the extract of Indongcho of the present invention can be administered in various oral and parenteral formulations during actual clinical administration, and when formulated, diluents such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants that are commonly used, or Formulated using excipients. Solid preparations for oral administration include tablets, pills, powders, granules and capsules, and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, lactose and gelatin, etc. Mix is prepared. In addition to simple excipients, lubricants such as magnesium styrate talc are also used. Liquid preparations for oral administration include suspensions, solutions, emulsions and syrups, and may include various excipients such as wetting agents, sweeteners, fragrances and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerol and gelatin may be used.

Dosage units may contain, for example, one, two, three or four times the individual dosage, or they may contain 1/2, 1/3 or 1/4 times. The individual dosage preferably contains an amount in which the effective drug is administered at one time, which usually corresponds to all, 1/2, 1/3 or 1/4 times the daily dose. The effective dose of Indongcho extract is concentration dependent but preferably 0.1 to 1 g / kg, more preferably 0.4 to 200 mg / kg, and may be administered 1-6 times a day.

In another aspect, the present invention provides a health food composition for promoting IGF-1 secretion containing Indongcho extract as an active ingredient.

In the present specification, the health food is a food that improves the function of the general food by adding an extract of Indongcho to the general food, and the Indongcho extract may be added to the general food, or may be prepared by encapsulation, powdering, and suspension. When ingested, it brings a specific effect on health, and unlike the general medicine because it is made of food as a raw material has the advantage that there is no side effect that can occur when taking long-term use of the drug.

When the phosphorus extract of the present invention is used as a food additive, the phosphorus extract may be added as it is or used together with other food or food ingredients, and may be appropriately used according to a conventional method. The blending amount of the active ingredient can be suitably determined according to the purpose of its use (prevention, health or therapeutic treatment). In general, the extract of Indongcho may be added in an amount of 0.0001 to 10% by weight, preferably 0.1 to 5% by weight based on the raw materials in the manufacture of food or beverage. However, in the case of prolonged ingestion for health and hygiene purposes or for health control purposes, the amount can be adjusted below the above range. In addition, when the health food of the present invention is used as the pharmaceutical composition, it is preferable to contain the extract of Indongcho within the measured toxicity range.

There is no particular limitation on the kind of food. Examples of foods to which the extract may be added include meat, sausage, bread, chocolate, candy, snacks, confectionary, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, teas, drinks Alcoholic beverages and vitamin complexes. Specifically, the health food containing the extract of Indongcho may include health foods and favorite products such as juice, tea, jelly, and juice made mainly from Indongcho, and include folk remedies for the purpose of edema, nephritis, urethritis, and the like. Can be mentioned.

Hereinafter, the present invention will be described in detail by way of examples.

However, the following examples are merely to illustrate the invention, but the content of the present invention is not limited to the following examples.

Example 1 Preparation of Indongcho extract 1

50 g of Indongcho dry powder were added to 500 ml of methanol and stirred at room temperature for 2 days. The solution obtained through the stirring process was filtered through a filter paper, concentrated under reduced pressure to remove methanol, and then lyophilized to remove moisture to prepare the extract of Indongcho of the present invention.

Example 2 Preparation of Indongcho Extract 2

50 g of Indongcho dried powder was added to 500 ml of distilled water, and extracted at 100 ° C. for 3 hours. After extracting for 3 hours to remove insoluble solids by filtration and centrifugation, the supernatant was concentrated under reduced pressure and lyophilized to prepare the extract of the present invention.

Example 3 Purification of Indongcho Extract

50 g of Indongcho dried powder was added to 500 ml of distilled water, and extracted at 100 ° C. for 3 hours. After extracting for 3 hours, the insoluble solids were removed by filtration and centrifugation, and the supernatant was flowed into a column (trade name DIAION) adsorbed with HP-20 resin at a flow rate of 20 ml / min. It was made to adsorb | suck to.

After distilled water was sufficiently flowed into the column to wash the resin, ethanol (95%) was flowed to recover the fraction containing the IGF-1 secretagogue component adsorbed on the resin. The recovered ethanol eluate was concentrated under reduced pressure at a temperature of 60 ° C. to obtain a concentrate, and the concentrate was dried under reduced pressure at 65 ° C. to obtain an active fraction of 2.5%.

Example 4 In vitro IGF-1 Secretion Inducing Effect of Indongcho Extract of the Present Invention

50 mg of the extract powder obtained in Example 3 was dissolved in 1 ml of distilled water to prepare a dosage solution.

The animals used in this example are SD male rats with a mean weight of about 200 g and 7 weeks old. The experimental animals were fasted for one day prior to administration of the extract of the present invention for the purpose of enhancing the responsiveness to the secretory stimulation of IGF-1. The number of animals was 6 for the control group and 7 for the experimental group. Subsequently, 1000 μl of the dose was forced into the rat by using an oral syringe. Blood collection was taken directly from the heart before and at 2 hours post-dose, and the last time was taken after 10 hours. In addition, anesthetics that may affect the secretion pattern of IGF-1 were not used during the experiment. Then, the quantification of IGF-1 in the collected sample was measured according to the provided protocol by purchasing an EIA (enzyme immunoassay) kit manufactured and sold by the American Diagnostic System Laboratory (DSL). The result is as shown in FIG.

As can be seen in Figure 1, the experimental group to which the Indongcho extract of the present invention was administered after 4 hours after administration significantly increased the concentration of IGF-1 in the blood and the control group. Therefore, it can be seen that the extract of Indongcho of the present invention increases the concentration of IGF-1 in the blood in animals. In addition, the elevated blood IGF-1 level can be confirmed to recover to its original state over time. The results showed that blood IGF-1 concentration reached its highest point 8 hours after the administration of the sample. Therefore, it is clear that the extract of Indongcho of the present invention induces the secretion of IGF-1.

Example 5 Manufacturing method of injection solution

Injection solution containing 10 mg of the active ingredient was prepared by the following method. 10 g of Indongcho extract was dissolved in 1,000 ml of physiological saline, and used as an injection by 0.2um sterile filtration.

The components of the injection solution are as follows.

Example 3 10 g

1,000 ml of saline

Example 6 Tablet manufacturing method

Tablets containing the active ingredient are prepared by the following method.

A tablet was prepared by mixing 600 g of Indongcho extract, 240 g of arginine, 140 g of crystalline cellulose, 10 g of magnesium stearate, and hydroxypropylmethylcellulose.

The components of the tablet are as follows.

600 g of Indongcho extract

Arginine 240 g

140 g of crystalline cellulose

10 g of magnesium stearate

10 g of hydroxypropyl methyl cellulose

Example 7 Application of Indongcho Extract to Milk

Milk ----------------------- 100g

Example 2 --------------------- 1g

Example 8 Application of Indongcho Extract to Orange Juice

Liquid fructose -------------------- 5%

Polydextrose --------------- 1%

Citric acid --------------------- 5%

Vitamin C -------------------- 0.02%

Example 9 -------------------- 2%

Orange Juice Concentrate ------------- 25%

Water ------------------------ 67%

Example 9 . Application of Indongcho Extract to Cosmetic Lotion

1,3-butylene glycol --------------- 5%

glycerine ----------------------- 5%

EDTA-2Na --------------------- 0.02%

trimethylglycine ----------------- 2.0%

cetanol ------------------------ 1.0%

glyceryl monostearate emulsifier --- 1.0%

polysorbate 60 ------------------ 1.2%

sorbitan sesquioleate ------------- 0.3%

cetyl 2-ethyl-hexaoate ----------- 4.0%

squalane ----------------------- 5.0%

dimethicone --------------------- 0.3%

glyceryl stearate ----------------- 0.5%

carbomer ----------------------- 0.15%

triethanoamine ------------------- 0.5%

imidazolidinyl urea ---------------- 0.2%

Example 3 ------------------------- 2.0%

Purified Water -------------------------- 71.8%

Example 10. Of Indongcho extract Application to cosmetic skin

1,3-butylene glycol --------------- 4.0%

dipropylene glycol ---------------- 5.0%

EDTA-2Na ---------------------- 0.02%

octyldodeceth-16 ----------------- 0.3%

PEG60 hydrogenate castor oil ------- 0.2%

Example 3 ------------------------- 0.5%

Purified Water -------------------------- 90%

Example 11 . Manufacture of beverages

Calcium lactate 50 mg

Citric acid 5 mg

Nicotinamide 10 mg

Riboflavin Sodium Hydrochloride 3 mg

Pyridoxine hydrochloride 2 mg

Arginine 30 mg

Example 2 100 mg

200 ml of water

With the above composition and content, drinks were prepared using conventional methods.

As described above, the Indongcho extract of the present invention exhibits a very high IGF-1 secretion promoting activity, and the raw material of this extract is a natural medicine that is harmless to the human body and has good absorption rate, which has been used for a long time. It can be usefully used for the treatment and prevention of

Claims (25)

Insulin-like Growth Factor-1 (IGF-1) secretion inducing and / or promoting composition comprising Lonicera japonica extract as an active ingredient The composition of claim 1, wherein the extract of Indongcho is a extract of flowers (gold) and fruit, roots and / or leaves and stems (dongdong, etc.). The method of claim 1, wherein the extract of Indongcho is Loniceroside A, Lonieroside B, C, hedragenin derivative (Lonicerin), Loganin (Loganin) and bogeloside ( Composition comprising at least one active ingredient selected from the group consisting of Iridoid glycosides such as Vogeloside, Epi-vogeloside (Epi-vogeloside) The composition of claim 1 or 2, wherein the extract of Indongcho is extracted under reflux. The composition of claim 1 or 2, wherein the phosphorus extract is extracted with water, an alcohol, or a mixed solvent of alcohol and water. 6. A composition according to any one of claims 1 to 5, wherein said composition has dwarfness therapeutic activity. The composition according to any one of claims 1 to 5, wherein the composition has protein promoting activity, blood glucose reduction and / or cell differentiation activity such as neuronal stem cells or myocytes. The composition according to any one of claims 1 to 5, wherein the composition has a type 1 and / or type 2 diabetes therapeutic activity. The composition according to any one of claims 1 to 5, wherein the composition is used to treat length growth delay, promote length growth, improve bone mineral density (prevent and cure osteoporosis), inhibit aging, improve gymnasticity, postmenopausal women Treatment of femoral degeneration, renal disease improvement, ischemic heart disease, chronic stress-related diseases, insomnia, metabolic disorders, decreased sexual capacity, decreased muscle strength and decreased motor performance in older women, cartilage regeneration and proliferation and glyco A composition characterized in that it has a protective activity of neurodegenerative arthritis including osteoarthritis and neurons by promoting the synthesis of saminoglycans. 6. A composition according to any one of claims 1 to 5, comprising a pharmaceutically acceptable carrier or excipient. The composition of claim 10, wherein the pharmaceutically acceptable carrier or excipient is at least one selected from base ingredients such as lactose, microcrystalline cellulose, magnesium stearate, and the like. The composition according to claim 10, wherein the mixing ratio of the pharmaceutically acceptable carrier or excipient and the phosphorus extract is 1: 1.5 to 1.5: 1. 6. The composition of claim 1, comprising a pharmaceutically acceptable carrier or excipient in the form of an edible beverage or food. 7. The composition according to claim 13, wherein the composition of the composition of Indongchocho extract is 0.0001 to 10% by weight. The composition according to any one of claims 1 to 5, comprising a carrier or excipient which is acceptable for the preparation of cosmetic compositions. 6. The IGF-1 secretion promoter according to any one of claims 1 to 5, comprising the composition as an active ingredient and optionally comprising one or more pharmaceutically acceptable carriers or excipients. 17. The formulation according to claim 16, further comprising an antacid. 17. The formulation according to claim 16, wherein the formulation is a tablet, powder, hard or soft capsule, suspension, injectable formulation, emulsion, suppository, unit dosage form or parenteral administration for parenteral administration. The preparation according to claim 16, wherein the content of the active ingredient is administered in the range of 25-24,000 mg / day per 1 kg of adult body weight. a) obtaining crude crude by refluxing the cauliflower with a water-soluble solvent; b) optionally, concentrating or filtering the extract; c) adsorbing onto HP-20 as an adsorbent; and d) adsorbing the column onto which the active ingredient is adsorbed. Washing with water and eluting the active ingredient with a water-soluble solvent; and e) optionally drying under reduced pressure at a suitable temperature under vacuum drying. The method of claim 20, further comprising the step of purifying by anion exchange chromatography and dialysis before step c). 21. The process according to claim 20 a) or d), wherein the water soluble solvent for extraction is water, lower alcohols or mixtures thereof. The method of claim 22, wherein the lower alcohol is ethanol, methanol, isophoropil alcohol, propanol, acetone. An extract of phosphorus (Indongcho) prepared by the method according to any one of claims 20 to 23. The method of claim 24, wherein the extract is Loniceroside A, B, C, hedragenin derivative, Loganin, Lonicerin, Vogeloside, Extract characterized in that it comprises at least one active ingredient selected from the group consisting of Iridoid glycosides such as Epi-vogeloside (Epi-vogeloside)